Φορτώνει......

Mutant KRAS is a druggable target for pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet t...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Zorde Khvalevsky, Elina, Gabai, Racheli, Rachmut, Itzhak Haim, Horwitz, Elad, Brunschwig, Zivia, Orbach, Ariel, Shemi, Adva, Golan, Talia, Domb, Abraham J., Yavin, Eylon, Giladi, Hilla, Rivkin, Ludmila, Simerzin, Alina, Eliakim, Rami, Khalaileh, Abed, Hubert, Ayala, Lahav, Maor, Kopelman, Yael, Goldin, Eran, Dancour, Alan, Hants, Yael, Arbel-Alon, Sagit, Abramovitch, Rinat, Shemi, Amotz, Galun, Eithan
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: National Academy of Sciences 2013
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3870687/
https://ncbi.nlm.nih.gov/pubmed/24297898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1314307110
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!